Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry

ABSTRACT Introduction: Quality of life (QOL) has been poorly characterized among patients with myasthenia gravis (MG) other than assessments performed within the clinical setting. Methods: Patients age ≥ 18 years who were diagnosed with MG and registered with the MG patient registry between July 1,...

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 58; no. 1; pp. 90 - 98
Main Authors Lee, Ikjae, Kaminski, Henry J., Xin, Haichang, Cutter, Gary
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.07.2018
Subjects
Demographics
gender
Men
MGFA registry
MG‐QOL15
Muscles
Myasthenia
Myasthenia gravis
Neuromuscular junctions
Patients
Quality of life
Thymectomy
Thymoma
Women
myasthenia gravis
thymectomy
gender
quality of life
MG-QOL15
MGFA registry
Online AccessGet full text
ISSN0148-639X
1097-4598
1097-4598
DOI10.1002/mus.26104

Cover

More Information
Summary:ABSTRACT Introduction: Quality of life (QOL) has been poorly characterized among patients with myasthenia gravis (MG) other than assessments performed within the clinical setting. Methods: Patients age ≥ 18 years who were diagnosed with MG and registered with the MG patient registry between July 1, 2013, and June 30, 2016, were included. Demographic information, disease related history, and QOL were compared between men and women using multivariable analysis. Results: A total of 1,315 subjects (827 women) were included. Women were significantly younger, had a younger age at symptom onset, and were more likely to have thymoma and thymectomy. The 15‐item Myasthenia Gravis Quality of Life scale (MG‐QOL15) was significantly worse in women. MG‐QOL15 score was comparable between women who had thymectomy and men with or without thymectomy. Discussion: QOL among MG patients is worse in women compared with men, but this disparity is eliminated in women who have undergone thymectomy. Muscle Nerve 58: 90–98, 2018
Bibliography:Conflicts of Interest
Funding
We appreciate the support from Myasthenia Gravis Foundation of America in establishing and maintaining the Myasthenia Gravis Patient Registry.
Author Gary Cutter serves as a member of Data and Safety Monitoring Boards: AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Opko Biologics, Neuren, Sanofi‐Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). Consulting or Advisory Boards: Atara Biotherapeutics, Bioeq GmBH, Cerespir Inc, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein‐Buendel Incorporated, Medimmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva pharmaceuticals, Transparency Life Sciences, TG Therapeutics. Author Henry Kaminski serves as Data and Safety Monitoring Boards for Novartis and the National Institutes of Health, receives consulting fees from Alnylam Pharmaceuticals, UCB, Biocatalyst, RA Pharmaceuticals, and Momenta Pharmaceuticals. He receives grant support from the Myasthenia Gravis Foundation of Illinois, Akari Pharmaceuticals, and the Muscular Dystrophy Association, and holds a patent related to technology to focus a complement inhibitor on the neuromuscular junction for the treatment of myasthenia gravis (U.S. patent no. 8,961,981).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0148-639X
1097-4598
1097-4598
DOI:10.1002/mus.26104